Financials · NUTX

Nutex Health Inc. (NUTX) financials

For the twelve months ended Sep 30, 2026, Nutex Health Inc. reported $796.53M of revenue and $211.14M of net income.

Revenue, TTM
$796.53M
Revenue growth, YoY
-18.8%
Net income, TTM
$211.14M
Net income growth, YoY
+14.7%
Net margin
26.5%
Free cash flow, TTM
$248.10M
EPS, diluted, TTM
$23.95
Cash
$249.91M
Total debt
$42.30M
P/E
6.31
P/S
1.67
Market cap
$1.33B
Annual revenue$875.26M
FY2016FY2025
Annual net income$70.79M
FY2016FY2025
Annual free cash flow$245.60M
FY2018FY2025

NUTX revenue and earnings growth

NUTX revenueQ3 2026$217.61M

Quarter YoY
-18.7%
QoQ
+3.3%
FY YoY
+82.4%
5Y CAGR
+26.1%
10Y CAGR
+112.1%

NUTX revenue was $217.61M in fiscal Q3 2026 (ended Sep 30, 2026), down 18.7% from a year earlier and up 3.3% from the prior quarter. For the full fiscal 2025 it was $875.26M, up 82.4% from fiscal 2024. Compound annual growth was +26.1% over 5 years and +112.1% over 10 years. It rose in 6 of the last 8 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

NUTX net incomeQ3 2026$40.23M

Quarter YoY
-27.4%
QoQ
-58.2%
FY YoY
+35.9%
5Y CAGR
-7.8%
10Y CAGR
+96.2%

NUTX net income was $40.23M in fiscal Q3 2026 (ended Sep 30, 2026), down 27.4% from a year earlier and down 58.2% from the prior quarter. For the full fiscal 2025 it was $70.79M, up 35.9% from fiscal 2024. Compound annual growth was -7.8% over 5 years and +96.2% over 10 years.

NUTX EPSQ3 2026$5.71

Quarter YoY
-26.4%
QoQ
-39.1%
FY YoY
+8.2%

NUTX diluted EPS was $5.71 in fiscal Q3 2026 (ended Sep 30, 2026), down 26.4% from a year earlier and down 39.1% from the prior quarter. For the full fiscal 2025 it was $10.48, up 8.2% from fiscal 2024.

NUTX free cash flowQ3 2026$73.14M

Quarter YoY
-26.3%
QoQ
+131.0%
FY YoY
12x
5Y CAGR
+57.3%
10Y CAGR
+137.4%

NUTX free cash flow was $73.14M in fiscal Q3 2026 (ended Sep 30, 2026), down 26.3% from a year earlier and up 131.0% from the prior quarter. For the full fiscal 2025 it was $245.60M, up about 12-fold from fiscal 2024. Compound annual growth was +57.3% over 5 years and +137.4% over 10 years. Fiscal 2025 is the highest of the 12 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$875.26M$479.95M$247.65M$219.29M$331.53M$274.03M$1.37M$1.37M$23.2K$0
Cost of revenue----$14.65M$909.8K$830.4K$507.6K$30.5K$0
Gross profit$444.28M$196.26M$34.77M$15.42M$179.28M$157.61M$536.0K$859.4K-$7.3K$0
Research and development----$285.9K$557.3K$768.1K$545.2K--
Selling, general and admin$51.65M$41.92M$33.23M$19.81M$5.46M$4.43M$3.67M$945.6K$1.81M$448.6K
Operating income$275.63M$130.70M-$31.77M-$406.60M$170.26M$153.17M-$6.90M-$840.4K-$5.69M-$448.6K
Interest expense$22.23M$19.93M$16.32M$12.49M$6.20M$6.43M$92.2K$109.8K$367.4K$2.6K
Pre-tax income$244.78M$109.83M-$48.49M-$419.65M$169.49M$145.74M-$7.12M---
Income tax$64.42M$15.02M-$5.07M$13.09M$965.7K$181.3K$0$0--
Net income$70.79M$52.10M-$45.79M-$424.78M$132.59M$105.97M-$7.12M-$950.1K$582.1K-$7.43M
EPS, basic$11.13$10.23-$10.39-$100.36$0.22$0.18-$1.96-$0.56$0.01-$0.19
EPS, diluted$10.48$9.69-$10.39-$100.36$0.22$0.18-$1.96-$0.56$0.01-$0.19
Diluted shares6.8M5.5M4.4M4.2M-4.9M3.6M1.7M83.7M39.7M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$185.57M$40.64M$22.00M$34.26M$36.12M$25.51M$1.07M$119.3K$11.7K$10.5K
Receivables-$232.45M$58.60M$57.80M$112.77M$18.3K$100.2K$186.2K$6.3K$0
Inventory$2.87M$2.85M$3.39M$3.53M$2.81M$0$27.0K$0$0-
Current assets$538.81M$292.48M$90.85M$97.97M$154.02M$157.1K$1.24M$305.4K$55.1K$507.9K
Goodwill$13.92M$13.92M$17.07M$17.01M$1.14M$0$3.47M$0-$0
Total assets$918.52M$655.32M$398.25M$431.75M$394.65M$169.9K$6.69M$449.4K$3.33M$510.8K
Current liabilities$157.91M$154.22M$58.31M$54.86M$37.69M$1.15M$4.61M$1.04M$959.8K$6.38M
Short-term debt$13.34M$14.39M$10.81M$12.55M$10.16M-----
Long-term debt$29.17M$22.47M$26.31M$23.05M$78.82M-$0$300.0K--
Total debt$42.51M$36.86M$37.12M$35.60M$88.98M$462.9K$0$300.0K--
Total liabilities$495.09M$466.79M$319.14M$311.42M$203.07M$1.30M$4.83M$1.95M$959.8K$6.38M
Shareholders' equity$329.45M$188.53M$79.11M$120.33M$191.58M$147.37M$50.84M-$1.50M-$997.2K-$5.87M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$248.13M$23.15M$1.26M$50.61M$173.43M$86.67M-$4.04M-$480.0K-$714.6K-$274.2K
Capital expenditures$2.53M$2.30M$9.50M$14.63M$36.93M$61.19M$84.0K$0--
Free cash flow$245.60M$20.85M-$8.24M$35.97M$136.51M$25.48M-$4.12M-$480.0K--
Investing cash flow-$5.24M-$5.61M-$11.24M-$4.34M-$36.98M-$61.19M-$748.2K-$117.0K$2.0K-$10.0K
Financing cash flow-$97.95M$1.09M-$2.27M-$48.13M-$125.85M-$7.97M$5.73M$704.6K$711.5K$172.4K
Share repurchases$5.00M$0$0-------
Stock-based compensation---$189.6K$4.03M$2.57M$450.1K$155.9K$924.3K$1.5K
Depreciation and amortization$20.53M$18.97M$17.59M$13.13M$7.66M$5.90M$156.1K$2.7K--

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY82.4%93.8%12.9%-33.9%21.0%19954.5%-0.0%5800.9%--100.0%
Net income growth, YoY35.9%---25.1%-----
EPS growth, YoY8.2%---------
Gross margin50.8%40.9%14.0%7.0%54.1%57.5%39.2%62.9%-31.6%-
Operating margin31.5%27.2%-12.8%-185.4%51.4%55.9%-504.8%-61.5%-24574.5%-
Net margin8.1%10.9%-18.5%-193.7%40.0%38.7%-520.8%-69.5%2512.6%-
Free cash flow margin28.1%4.3%-3.3%16.4%41.2%9.3%-301.9%-35.1%--
Return on equity21.5%27.6%-57.9%-353.0%69.2%71.9%-14.0%---
Return on assets7.7%7.9%-11.5%-98.4%33.6%62387.7%-106.3%-211.4%17.5%-1454.9%
Current ratio3.411.901.561.794.090.140.270.290.060.08
Debt to equity0.130.200.470.300.460.000.00---

Source: XBRL data Nutex Health Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

NUTX peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
NUTX$796.53M-18.8%$211.14M26.5%$1.33B
V$45.90B+14.8%$23.50B51.2%$761.17B
MA$36.29B+15.3%$16.96B46.7%$571.32B
BABACN¥1.02T+2.7%CN¥103.59B10.1%$255.28B
ACN$74.18B+6.5%$8.37B11.3%$170.10B
UBER$56.53B+13.9%$3.46B6.1%$145.32B
PDDCN¥431.85B+9.7%CN¥97.84B22.7%$114.58B
DASH$17.06B+35.0%$1.06B6.2%$78.89B
MELI$38.52B+47.1%$1.89B4.9%$77.70B

NUTX FAQ

9 questions
  • What is NUTX revenue?
    Nutex Health Inc. (NUTX) reported $796.53M of revenue for the twelve months ended Sep 30, 2026. That is down 18.8% from the year before. Revenue for fiscal 2025 was $875.26M.
  • Is NUTX profitable?
    Yes. Nutex Health Inc. earned $211.14M in net income for the twelve months ended Sep 30, 2026, a net margin of 26.5%.
  • How much cash and debt does NUTX have?
    Nutex Health Inc. reported $249.91M in cash and cash equivalents and $42.30M of debt on its most recent balance sheet in SEC filings.
  • How fast is NUTX revenue growing?
    Nutex Health Inc.'s revenue changed +82.4% in fiscal 2025, to $875.26M. Its compound annual growth rate was +26.1% over 5 years and +112.1% over 10 years.
  • What is NUTX gross margin?
    Nutex Health Inc.'s gross profit was $380.67M on $796.53M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 47.8%.
  • What is NUTX free cash flow?
    Nutex Health Inc. generated $248.10M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $258.45M less capital expenditures.
  • What is NUTX earnings per share?
    Diluted earnings per share were $23.95 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did NUTX last report financial results?
    The latest statements here come from Nutex Health Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this NUTX financial data come from?
    Quantisnow builds these statements from the structured XBRL data Nutex Health Inc. files with the SEC. It is provided for information only and is not investment advice.